News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

National Cancer Institute Contracts PGXL Technologies to Advance Early Cancer Diagnosis and Treatment

10/31/2013 9:16:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOUISVILLE, Ky., Oct. 30, 2013 /PRNewswire/ -- PGXL Technologies has received a contract to help the National Cancer Institute further the science of early cancer diagnosis through the detection of circulating tumor cells (CTCs). The $300,000 contract was one of only four awarded in the quest to expand the types of detectable CTCs.


"There was no other applicant who could isolate and manipulate individual cells the way we can," says Dr. Kevin Goudy, who leads the PGXL Technology team that will conduct the research. "The contract recognizes that unique capability, and gives us the chance to make a significant contribution to cancer diagnosis and treatment."

PGXL uses DEPArray Technology to work with individual cells. Developed by Silicon Biosystems, DEPArray is the most advanced single-cell-isolation technology in the world. PGXL and Silicon Biosystems will collaborate to develop a way to identify and isolate CTCs that are invisible to conventional technology. The DEPArray enables clinical researchers and pharma sponsors to obtain the level of data fidelity and resolution needed in cancer biomarker discovery and translational research.

PGXL Technologies is the sister company of PGXL Laboratories, a global leader in the clinical application of pharmacogenetic and molecular diagnostic testing for personalized medicine. It is PGXL Technologies' mission to identify and commercialize new technologies to improve medical outcomes and advance the cause of personalized medicine.

PGXL Laboratories was the first lab in the country CLIA-certified specifically to conduct pharmacogenetic tests. It offers pharmacogenetic testing and interpretive services, and developed one of the first commercial CYP2C9/VKORC1 tests for accurate anticoagulant dosing. Along with its clinical practice, PGXL performs contract research for manufacturers of pharmaceuticals and medical equipment.

For more information on PGXL Technologies, visit

About Silicon Biosystems
Silicon Biosystems is a medical device manufacturer leading the field in the detection and recovery of single cells for cancer research and prenatal testing. The company manufactures and sells the DEPArray platform, a labon-a-chip technology able to isolate and manipulate cells in suspension with a microelectronic array. The approach, patented by Silicon Biosystems, offers the unique ability to control individual cells and micro-particles inside a disposable cartridge. The DEPArray platform makes it possible to find, sort, and recover individual cells for further analysis or culturing. For more information on Silicon Biosystems visit

Tom Johnson

SOURCE PGXL Technologies

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus